All-in-one system addresses critical need for fully automated, high-throughput real-time PCR testing

0

Posted: October 27, 2021 at 9:22 a.m. MDT|Update: 2 hours ago

  • A true ‘sample to response’ molecular diagnostic system designed for high throughput testing, providing a fast and transparent workflow for clinical laboratories
  • Uses Seegene’s patented and state-of-the-art high multiplex real-time PCR technologies to deliver “real” Ct values ​​of individual pathogens in a single channel.
  • Uses Seegene’s broad menu of molecular diagnostics for syndromic testing, for detection of SARS-CoV-2 and its variants.

Seoul, South Korea, October 27, 2021 / PRNewswire / – South Korea Seegene Inc., Leading Developer of Molecular Diagnostics (MDx), (KQ 096530) meets the needs of small, medium and large hospitals and COVID-19 laboratories with its fully automated STARlet-AIOS: All-in-One System (AIOS) . First unveiled at the 2021 AACC Annual Scientific Meeting and Clinical Labs Exhibition at Atlanta, the modular system supports a “hands-free” PCR workflow, automating everything from nucleic acid extraction to interpretation of results. This can help sites increase their testing capacity while reducing the burden on laboratory and hospital staff.

Logo (PRNewsfoto / Seegene Inc.)

“Seegene has played a critical role in the global response to the COVID-19 pandemic, in large part due to our forward-looking strategy. We acted quickly from day one, quickly developing a reliable test for the novel coronavirus and then going multiplexed. tests that can detect emerging variants of SARS-CoV-2, ”said Dr. Jong Yoon Chun, Founder and CEO of Seegene. “As we look to the future, the most pressing diagnostic need will be for cost-effective, high-throughput automated systems that can eliminate any remaining test bottlenecks. Our all-in-one system specifically addresses this need in hospitals and laboratories of all sizes. “

More than 3.75 billion people worldwide have now received at least one dose of a COVID-19 vaccine. As the daily number of cases and deaths decline, many countries are relaxing their restrictions and preparing to live with the virus. Doing so safely will require continuous monitoring, with accurate PCR testing and fast turnaround times.

The modular design of STARlet-AIOS: All-in-One System unites two stand-alone instruments, the STARlet IVD and the CFX96 ™ Dx real-time PCR system, with a bespoke robotic arm. This unique engineering allows customers to purchase the complete AIOS system or integrate existing Seegene instruments already in use. With its compact and intuitive design, AIOS is accessible to small to medium-sized hospitals and clinics, as well as large organizations.

Seegene’s current portfolio with an extensive menu of tests including GI, HPV, STI, respiratory tests as well as a SARS-CoV-2 test suite detecting a wide range of variants (i.e., Alpha, Beta, Gamma, Delta , Epsilon, kappa, Lambda, Mu, etc.) can all be processed using AIOS. The system will also be compatible with newly developed tests and tests from Seegene MOBILE STATION, an innovative laboratory-on-wheels initiative that provides mass testing capability to communities that otherwise would not have the necessary infrastructure.

Meanwhile, the company plans to introduce Allplex ™ Respiratory Virus Master Assay, in late 2021, a single-tube syndromic test that can differentiate COVID-19 from other common respiratory pathogens, such as influenza, RSV, l adenovirus, parainfluenza, metapneumovirus, human rhinovirus. The introduction of the new test will help doctors treat cases more effectively, differentiating between the pathogens responsible for COVID-19 and the respiratory viruses of the common flu, which can increase in winter.

View original content to download multimedia:

SOURCE Seegene Inc.

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.

Leave A Reply

Your email address will not be published.